MedTrace Logo

An Open-label, Single Dose, Parallel Design, Phase 1 Clinical Study of LCB01-0371

NCT02529241 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2016-04-08

No results posted yet for this study

Summary

To investigate pharmacokinetics, safety and tolerability of LCB01-0371, LCB01-0371-B after a single oral dose in healthy male subjects.

To investigate safety, tolerability of LCB01-0371 after a single oral dose in healthy male subjects.

Conditions

  • Healthy

Interventions

DRUG

Group 1:LCB01-0371

1. Period:LCB01-0371 Tablet 400 mg 2. Period: LCB01-0371 Tablet 400 mg

DRUG

Group 2:LCB01-0371

1. Period:LCB01-0371 Tablet 800 mg 2. Period: LCB01-0371 Tablet 1200 mg

Sponsors & Collaborators

  • LigaChem Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Kyun-Seop Bae, MD PhD · Asan Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02529241 on ClinicalTrials.gov